Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

PHASE3RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

January 31, 2028

Conditions

Growth Hormone Deficiency (GHD)

Interventions

DRUG

LUM-201

1.6 mg/kg/day, administered orally once daily

OTHER

Matched Placebo (Capsules)

Administered orally once daily

Trial Locations (1)

RECRUITING

Lumos Pharma Investigational Site, Greenwood Village